Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03264898 · ClinicalTrials.gov registry record
Comparative Effectiveness of FITs With Colonoscopy
A clinical trial, sponsored by Barcey T. Levy.
- Completed
- Registry status
- 3,761
- Enrollment target
NCT03264898: Completed study, sponsored by Barcey T. Levy.
NCT03264898 is a clinical trial that has completed, run by Barcey T. Levy. The registered enrollment target is 3,761 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03264898 has completed, sponsored by Barcey T. Levy.
- COMPLETED
- Registry status
- 3,761 participants
- Enrollment target
Study Summary
Colorectal cancer is a preventable and/or a treatable cancer, but at least 43% of the United States population is not up-to-date with screening. Although 90% of colorectal cancer screening is done using colonoscopy, most other countries use fecal immunochemical tests, reserving colonoscopy for those with a positive fecal immunochemical test. This project will provide the foundation for a paradigm shift for colorectal cancer screening in the United States by identifying how well 5 different FITs work for detecting screening relevant neoplasia, thus reducing morbidity and mortality for colorectal cancer.
Primary Outcome
Individual FIT brand results of negative, positive, or invalid
Interventions
- DEVICE Fecal immunochemical test (FIT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,761 participants |
| Start Date | 2017-10-02 |
| Est. Completion | 2023-10-01 |
What the finished NCT03264898 record still lists
NCT03264898 is an observational study that tracks outcomes without assigning an intervention. Its 3,761 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Fecal immunochemical test (FIT) is the first listed.
NCT03264898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03264898 about?
NCT03264898 is a clinical study titled "Comparative Effectiveness of FITs With Colonoscopy". Colorectal cancer is a preventable and/or a treatable cancer, but at least 43% of the United States population is not up-to-date with screening. Although 90% of colorectal cancer screening is done using colonoscopy, most other countries use fecal immunochemical tests, reserving colonoscopy for those...
What is the current status of trial NCT03264898?
This trial is currently completed. The enrollment target is 3,761 participants. The study started on 2017-10-02. Estimated completion is 2023-10-01.
What interventions are being tested in trial NCT03264898?
The interventions under investigation include: Fecal immunochemical test (FIT) (DEVICE).
Who is sponsoring clinical trial NCT03264898?
This trial is sponsored by Barcey T. Levy, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06172660 · 3,750 participants
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
- NCT06298253 · 3,750 participants · NA
Behavioral Economics to Implement a Traffic Light Nutrition Ranking System: Study 2
- NCT04573660 · 3,784 participants
Abbott Vascular Medical Device Registry
- NCT06076304 · 3,720 participants · Phase 4
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI